| 000 | 01612 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516053800.0 | ||
| 264 | 0 | _c20111212 | |
| 008 | 201112s 0 0 eng d | ||
| 022 | _a1520-4804 | ||
| 024 | 7 |
_a10.1021/jm200590k _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHuhtiniemi, Tero | |
| 245 | 0 | 0 |
_aStructure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2. _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cOct 2011 |
||
| 300 |
_a6456-68 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAcetylation |
| 650 | 0 | 4 |
_aApoproteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aCrystallography, X-Ray |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 | _aMolecular Mimicry |
| 650 | 0 | 4 |
_aPeptides _xchemical synthesis |
| 650 | 0 | 4 | _aProtein Binding |
| 650 | 0 | 4 |
_aSirtuin 1 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSirtuin 2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSolid-Phase Synthesis Techniques |
| 650 | 0 | 4 | _aStereoisomerism |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xmetabolism |
| 700 | 1 | _aSalo, Heikki S | |
| 700 | 1 | _aSuuronen, Tiina | |
| 700 | 1 | _aPoso, Antti | |
| 700 | 1 | _aSalminen, Antero | |
| 700 | 1 | _aLeppänen, Jukka | |
| 700 | 1 | _aJarho, Elina | |
| 700 | 1 | _aLahtela-Kakkonen, Maija | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 54 _gno. 19 _gp. 6456-68 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm200590k _zAvailable from publisher's website |
| 999 |
_c21135645 _d21135645 |
||